Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2947 - Prospective study of cetuximab with cisplatin plus docetaxel followed by concurrent radiotherapy plus cetuximab and cisplatin in patients with chemotherapy-naive metastatic nasopharyngeal carcinoma


09 Oct 2016


Poster display


Tongyu Lin


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


T. Lin, M. Zhang, H. Huang, X. Li, Y. Huang, C. Chen, Z. Wang, X. Fang

Author affiliations

  • Department Of Medical Oncology, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN


Abstract 2947


Metastatic nasopharyngeal carcinoma (mNPC) is generally considered as incurable using conventional therapy. We incorporated cetuximab into the induction therapy and subsequent chemoradiotherapy to treat mNPC in a prospective study.


Between Jul 2006 to Dec 2014, eligible patients (≥18 years old) with chemotherapy-naive mNPC, including initial metastases (IM) and first relapse metastases (RM), entered into the trial according to their willingness. Patients in the study group were treated with docetaxel 75 mg/m2, cisplatin 75 mg/m2, and cetuximab 250 mg/m2 days 1, 8, and 15 (after an initial loading dose of 400 mg/m2), repeated every 3 weeks up to a maximum of 6 cycles, followed by IMRT (68-70 Gy) with concurrent cetuximab 250 mg/m2 weekly for six cycles and cisplatin 75 mg/m2 per three weeks for two cycles, and maintenance capecitabine plus celecoxib for 3 years. Patients in the control group received conventional chemoradiotherapy.


Totally 43 patients in the study group (17 IM and 26 RM patients), and 66 patients in the control group were enrolled. The ORR and CRR after induction chemotherapy were 79.1% and 34.9% for the study group and 47% and 3% for the control group respectively. With a median follow-up of 60 months, 5yOS and PFS were 28.9% and 16.7% in the study group and 10.9% and 0% in the control group, respectively. In the study group the ORR and CRR were higher in the IM than in the RM subgroup (94.1% vs. 69.2%, 52.9% vs. 23.1%, both p 36 months, 10 of them were still alive with disease-free survival time ranging from 46 to 92+ months. Five patients (11.6%) had grade 3 cetuximab-related acneiform rash. Occurrence of other most common toxicities were similar between the two groups.


The cetuximab-containing induction and consolidation chemoradiation in patients with chemotherapy-naive mNPC resulted in excellent long-term disease-free survival and safety, indicating that mNPC is potential curable, especially in patients with initial metastases.

Clinical trial identification

Legal entity responsible for the study

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China


Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; Sun Yat-sen University Cancer Center


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings